Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-06-25

Clinical Trial Update: A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for ALKS 5461 in major depressive disorder; study completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ALKS 5461 (ALKS-5461)

Snippet

Sponsor: Alkermes, Inc. | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED | Results posted: 2019-06-25